Home / Market News / $BHC

$BHC news and market catalysts

The 14 most recent market catalysts affecting $BHC, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

14 catalysts 3 high impact 9 bullish 0 bearish Pharmaceuticals
Nov 19, 2026 Corporate Catalyst Neutral Impact 55
Prospect Markets Nominates Kevin Gopaul for Election to Bausch Health Board of Directors
Prospect Markets has announced its nomination of Kevin Gopaul, CEO of VanEck Canada, to the Board of Directors of Bausch Health Companies Inc. This event signifies potential change…
Nov 11, 2026 Corporate Catalyst Bullish Impact 55
Barclays Maintains Bausch Health Hold Rating and Raises Price Target
Barclays has maintained its 'Hold' rating on Bausch Health Companies Inc. but has raised its price target from an unspecified previous level to $9. This action indicates that while…
Nov 4, 2026 Corporate Catalyst Neutral Impact 75
Bausch Health Discusses Strategic Options for Bausch + Lomb
Bausch Health (BHC) disclosed during its Q3 2026 earnings call that it is actively evaluating strategic options for its significant 88% ownership in Bausch + Lomb (BLCO), including…
Oct 29, 2026 Corporate Catalyst Bullish Impact 55
RBC Raises Price Target on Bausch Health to $10 From $9
RBC has adjusted its price target for Bausch Health Companies Inc. upwards from $9 to $10. This change reflects RBC's updated assessment of the company's value, likely influenced b…
Oct 28, 2026 Corporate Catalyst Bullish Impact 85
Bausch Health Announces Third Quarter 2026 Financial Results and Raises Guidance
Bausch Health reported impressive Q3 2026 results, with consolidated revenues up 10% and adjusted EBITDA increasing by 32% year-over-year. The company also highlighted that, exclud…
Oct 28, 2026 Corporate Catalyst Bullish Impact 55
Bausch Health Authorizes $50 Million Share Repurchase Program
Bausch Health's Board of Directors has approved a share repurchase program of up to $50 million, starting in November 2026 and ending in November 2027. The stated purpose is to man…
Oct 28, 2026 Corporate Catalyst Neutral Impact 65
Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027
Bausch Health is redeeming $643 million of 8.500% senior notes due 2027, using cash on hand. This action is significant because it reduces the company's overall debt and, more impo…
Oct 19, 2026 Corporate Catalyst Bullish Impact 55
Bausch Health Canada Announces Expanded Public Reimbursement For PrOKEDI 75 Mg And 100 Mg, With Coverage Now Available In Seven Provinces And Multiple Federal Drug Plans
Bausch Health Canada has secured expanded public reimbursement for its schizophrenia treatment, PrOKEDI, across seven Canadian provinces and multiple federal drug plans. This devel…
Oct 12, 2026 Corporate Catalyst Bullish Impact 65
Bausch Health’s Salix Says Cirrhosis Care Pathway Pilot Raised Hepatic Encephalopathy Treatment Rates From 60.2% To 64.9%
The headline is a positive indicator for Bausch Health (BHC) as it highlights the success of a care pathway pilot for hepatic encephalopathy, a condition treated by their Salix div…
Sep 8, 2026 Corporate Catalyst Neutral Impact 65
Bausch Health Announces SILIQ Now Listed Under Alberta's Public Drug Plan For Eligible Moderate To Severe Plaque Psoriasis Patients
The listing of SILIQ under Alberta's public drug plan provides Bausch Health (BHC) with increased market penetration and potential revenue growth for this specific product within C…
Jul 29, 2026 Corporate Catalyst Bullish Impact 75
Bausch Health Companies Raises FY2026 Sales Guidance from $10.670B-$10.920B to $10.790B-$11.040B vs $10.773B Est
Bausch Health Companies (BHC) has raised its FY2026 sales outlook from a range of $10.670 billion-$10.920 billion to $10.790 billion-$11.040 billion, surpassing the analyst estimat…
Jul 29, 2026 Corporate Catalyst Bullish Impact 85
Bausch Health Companies Q2 Adj. EPS $1.26 Beats $1.04 Estimate, Sales $2.852B Beat $2.661B Estimate
This headline is a significant corporate catalyst for Bausch Health (BHC). The substantial beat on both adjusted EPS and sales indicates strong underlying business performance, pot…
Jul 29, 2026 Corporate Catalyst Bullish Impact 92
Bausch Health Companies Q2 Adj. EPS $1.26 Beats $1.06 Estimate, Sales $2.852B Beat $2.679B Estimate
Bausch Health Companies announced Q2 adjusted EPS of $1.26, surpassing the consensus estimate of $1.06 by 17.76%, and sales of $2.852 billion, beating the $2.679 billion estimate b…
Jul 28, 2026 Corporate Catalyst Neutral Impact 65
Bausch Health's Bausch Health, Canada Announces PrELIDEL Cream Listed Under Alberta's Public Drug Plan
The listing of PrELIDEL Cream under Alberta's public drug plan is a direct positive for Bausch Health, as it broadens the availability and affordability of their product within a k…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.